Skip to content

Vienna Preserflo Cohort Study

Vienna Preserflo Microshunt Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04541524
Enrollment
70
Registered
2020-09-09
Start date
2020-06-05
Completion date
2020-11-30
Last updated
2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy, Self, Glaucoma, Glaucoma Surgery, Post-Op Complication, Safety Issues

Brief summary

The Vienna Preserflo Microshunt Cohort Study is an observational study with a prospective postoperative examination in all glaucoma patients who had received a Preserflo Microshunt (PMS) as standalone procedure or in combination with cataract extraction in the time period between January and November 2019 at the Department of Ophthalmology, Medical University of Vienna. It is estimated that approximately 70 patients will be included of this cohort. The cohort will be invited for a prospective postoperative examination after 12 (±5) months of follow up. This examination shall comprise best corrected visual acuity, visual field test, intraocular pressure (IOP) measurement, slit lamp examination, fundus examination (optic disc and retina), gonioscopic assessment of PMS position, anterior segment optical coherence tomography (OCT) (shunt position, anterior chamber angle assessment, limbus shape analysis), corneal pachymetry, specular microscopy of corneal endothelial cells. Additionally, retrospective information concerning IOP, medication and visual fields of all patients will be collected from the Department of Ophthalmology as well as from the referring ophthalmologists where possible. Additionally, we will perform a comparison between two groups to compare differences in outcome measures.

Detailed description

During the inclusion period two slightly different surgical approaches have been used. At the beginning of the surgery, the conjunctiva is opened and the Tenon capsule is getting dissected from the sclera. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. The outcomes of these two groups will be compared.

Interventions

The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years

Inclusion criteria

* Glaucoma patients who received a PMS in the time period between January and November 2019 at the Department of Ophthalmology, Medical University of Vienna, Austria, will be invited

Exclusion criteria

* Unwilling or unable to give informed consent. * Pregnancy or lactation

Design outcomes

Primary

MeasureTime frameDescription
IOPone yearIOP in mmHg
Full successone yearIOP below 21 and IOP reduction of at least 20% from baseline without medication
Qualified successone yearIOP below 21 and IOP reduction of at least 20% from baseline with or without medication
Complicationsone yearNumber of complications per eye

Secondary

MeasureTime frameDescription
OCT - shunt clearanceone yearShunt-cornea angle as determined by anterior segment OCT
Re-intervention rate rateone yearProportion of eyes requiring either needling revision of filtering bleb revision or any other glaucoma surgery
Corneal endothelial cell countone yearCorneal endothelial cell count in specular microscopy of corneal endothelium
OCT - shunt lengthone yearShunt length in the anterior chamber as determined by anterior segment OCT
Medication rateone yearNumber of patients who needed again eye pressure lowering medication
Average medicationone yearAverage number of different eye pressure lowering medication
OCT - shunt entryone yearShunt position in chamber angle as determined by anterior segment OCT

Countries

Austria

Contacts

Primary ContactClemens Vass, Univ.Prof
clemens.vass@meduniwien.ac.at0043140400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026